0001209191-22-057985.txt : 20221118
0001209191-22-057985.hdr.sgml : 20221118
20221118184204
ACCESSION NUMBER: 0001209191-22-057985
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221116
FILED AS OF DATE: 20221118
DATE AS OF CHANGE: 20221118
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kumar Neil
CENTRAL INDEX KEY: 0001742485
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38959
FILM NUMBER: 221403153
MAIL ADDRESS:
STREET 1: C/O EIDOS THERAPEUTICS, INC.
STREET 2: 101 MONTGOMERY STREET, SUITE 2550
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BridgeBio Pharma, Inc.
CENTRAL INDEX KEY: 0001743881
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 421 KIPLING STREET
CITY: PALO ALTO
STATE: CA
ZIP: 94301
BUSINESS PHONE: (650) 391-9740
MAIL ADDRESS:
STREET 1: 421 KIPLING STREET
CITY: PALO ALTO
STATE: CA
ZIP: 94301
FORMER COMPANY:
FORMER CONFORMED NAME: BridgeBio Pharma LLC
DATE OF NAME CHANGE: 20180618
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-11-16
0
0001743881
BridgeBio Pharma, Inc.
BBIO
0001742485
Kumar Neil
C/O BRIDGEBIO PHARMA, INC.
421 KIPLING STREET
PALO ALTO
CA
94301
1
1
0
0
CEO and President
Common Stock
2022-11-16
4
M
0
68706
A
4881903
D
Common Stock
2022-11-16
4
F
0
34066
9.64
D
4847837
D
Common Stock
2022-11-17
4
S
0
34640
9.3997
D
4813197
D
Common Stock
1612722
I
See Footnote
Common Stock
1195686
I
See Footnote
Restricted Stock Units
2022-11-16
4
M
0
5130
0.00
D
Common Stock
5130
30776
D
Restricted Stock Units
2022-11-16
4
M
0
2394
0.00
D
Common Stock
2394
21548
D
Restricted Stock Units
2022-11-16
4
M
0
61182
0.00
D
Common Stock
61182
305910
D
Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 68,706 shares of Common Stock underlying the Reporting Person's RSUs.
Represents the weighted average sale price of the shares sold from $9.16 to $9.65 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions as reported herein.
The shares are held by Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
The shares are held by Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
The RSUs vest in sixteen quarterly installments after May 16, 2020, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date.
The RSUs vest in sixteen quarterly installments after February 16, 2021, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date.
The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022. Thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service to the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.
/s/ Brian C. Stephenson, Attorney-in-Fact
2022-11-18